Milo Aims Follistatin Therapy at Muscular Dystrophy
Just a year out of the gate and with less than $1 million in funding, Milo Biotechnology LLC already has an FDA-sanctioned investigational new drug (IND) application and is in human trials with follistatin, a protein that increases muscle strength and prevents atrophy.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter